AndreaBozzo/ceres-open-data-index huggingface dataset:
Small airway inflammation in asthma

Asthma was originally described as an inflammatory disease that predominantly involves the central airways. Pathological and physiological evidence reported during the past few years suggests that the inflammatory process extends beyond the central airways to the peripheral airways and the lung parenchyma. The small airways are capable of producing T-helper-2 cytokines, as well as chemokines, and they have recently been recognized as a predominant site of airflow obstruction in asthmatic persons. The inflammation at this distal site has been described as more severe than large airway inflammation. These findings are of great clinical significance, and highlight the need to consider the peripheral airways as a target in any therapeutic strategy for treatment of asthma.
Weekly Cumulative Influenza Vaccination Coverage, Children 6 months through 17 years, United States

Weekly Cumulative Influenza Vaccination Coverage, Children 6 months through 17 years, United States
• Influenza vaccination coverage among children is assessed through the National Immunization Survey-Flu (NIS-Flu) annually, providing weekly influenza vaccination coverage estimates for children 6 months–17 years based upon parental report. (https://www.cdc.gov/vaccines/imz-managers/nis/about.html)
o NIS-Flu is a national random-digit-dialed cellular telephone survey of households conducted during the flu season (October-June).
• Additional information about NIS-Flu methods and estimates from the 2019-2020 season are available at: https://www.cdc.gov/flu/fluvaxview/coverage-1920estimates.htm.
Vector algebra in the analysis of genome-wide expression data

Background
          Data from thousands of transcription-profiling experiments in organisms ranging from yeast to humans are now publicly available. How best to analyze these data remains an important challenge. A variety of tools have been used for this purpose, including hierarchical clustering, self-organizing maps and principal components analysis. In particular, concepts from vector algebra have proven useful in the study of genome-wide expression data.
        
        
          Results
          Here we present a framework based on vector algebra for the analysis of transcription profiles that is geometrically intuitive and computationally efficient. Concepts in vector algebra such as angles, magnitudes, subspaces, singular value decomposition, bases and projections have natural and powerful interpretations in the analysis of microarray data. Angles in particular offer a rigorous method of defining 'similarity' and are useful in evaluating the claims of a microarray-based study. We present a sample analysis of cells treated with rapamycin, an immunosuppressant whose effects have been extensively studied with microarrays. In addition, the algebraic concept of a basis for a space affords the opportunity to simplify data analysis and uncover a limited number of expression vectors to span the transcriptional range of cell behavior.
        
        
          Conclusions
          This framework represents a compact, powerful and scalable construction for analysis and computation. As the amount of microarray data in the public domain grows, these vector-based methods are relevant in determining statistical significance. These approaches are also well suited to extract biologically meaningful information in the analysis of signaling networks.
Interaction between mevalonate pathway and retinoic acid-induced
differentiation

All trans retinoic acid (ATRA) is a potent inducer of differentiation of HL-60 cell line. The pretreatment of the cells by compactin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl (HMG) CoA reductase, during 24 hours, enhances the ATRA-induced cell differentiation. At 50 nM, the percentage of cell differentiation is 34.9% ± 2 and 73% ± 2.96 in the control and compactin-treated cells, respectively. The removal of compactin boosts the level of HMG-CoA reductase and therefore the biosynthesis of sterol and nonsterol isoprenoid compounds. The participation of sterol and nonsterol pathway was then investigated. The supply of an excess of cholesterol (up to 80 μg/ml of LDL) leads to a significant decrease of cell differentiation by ATRA from 78% ± 0.1 to 54% ± 2.8. A concomitant decrease of cell growth (51% ± 6.4) was observed. The pretreatment of cells by the geranylgeranyltransferase inhibitor (GGTI-298) has no effect on the cell differentiation process. By contrast, the farnesyltransferase inhibitors (FTI-II and FTI-277) completely abolish the ATRA-induced differentiation, thus confirming the involvement of farnesylated proteins in the differentiation mechanism.
Patent AT-E401085-T1: [Translated] METHODS OF PROTECTION AGAINST GENOTOXIC MUtagenesis

A method for protecting against mutational damage in mammalian cells induced by irradiation comprising administering a phosphorothioate or phosphorothiate metabolite selected from the group consisting S-2-(3-aminopropylamino)ethylphosphorothioic acid, S-1-(aminoethyl) phosphorothioic acid, S-Ä2-(3-methylaminopropyl) aminoethylÜ phosphorothioate acid, S-2-(4-aminobu-lamino) ethylphosphorothioic acid, 3-Ä(2-mercaptoethyl) aminoÜ propionamide p-toluenesulfonate, S-1-(2-hydroxy-3-amino) propyl phosphorothioic acid, 2-Ä3-(methylamino) propylaminoÜ ethanethiol, 2-(aminopropylamino)ethanethiol, S-2-(5-aminopentylamino) ethyl phosphorothioic acid, 1 Ä3-(3-(aminopropyl) thiazolidin-2-Y1Ü-D-gluco-1,2,3,4,5 pentanepentol dihydrochloride and N,N'-(dithiodi-2,1-ethanediyl)bis-1,3-propanediamme to the mammal before or up to 3 hours after irradiation.
The Child Welfare Information Technology System Project Lifecycle, Part 1

Through the webinar series, "Back to Basics", the Division of State Systems within the Children's Bureau, is offering a venue for information sharing and discussion. The second webinar of the series, “The Child Welfare Information Technology System Project Lifecycle, Part 1”, reviews the initial project stages including planning, procurement, relationship management and effective management of priorities, with two experienced child welfare Information System managers sharing their perspectives. Webinar 3 will cover the latter half of the project life cycle.

Metadata-only record linking to the original dataset. Open original dataset below.
2015 CMHS Uniform Reporting System (URS) Table for Maryland

2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Maryland. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 527331: Methyl 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]propanoate

Chemical compound data from PubChem database. IUPAC Name: methyl 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]propanoate. Molecular Formula: C17H19NO3. Molecular Weight: 285.34. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Articular cartilage and changes in arthritis: Matrix degradation

While many proteases in articular cartilage have been described, current studies indicate that members of two families of metalloproteases – MMPs and the ADAMTSs – are responsible for the degradation of the major components of this tissue. Collagenases (MMPs) make the first cleavage in triple-helical collagen, allowing its further degradation by other proteases. Aggrecanases (ADAMTSs), in conjunction with other MMPs, degrade aggrecan, a component of the proteoglycan aggregate. Anti-neoepitope antibodies that recognize the cleavage products of collagen and aggrecan generated by these enzymes are now available and are being used to detect the sites of action and to quantitate degradation products.
Localities for 2022

The CY 2022 Medicare Physician Fee Schedule updates various related policies and CPT/HCPCS codes for the new calendar year.  This includes implementing all recent legislation directed by Congress starting January 1, 2022 and the upcoming conversion factor of $34.6062.  The Geographic Practice Cost Index (GPCI) work floor of 1.0 continues to be extended through the end of CY 2023.  Medicare co-insurance for certain colorectal cancer screening tests will begin its phased in waiver. Mental Health services through telehealth will be expanded following the end of the PHE.
Patent AT-E267269-T1: [Translated] METHOD FOR PRODUCING A HOT STRIP FROM A HIGH MANGANEOUS STEEL

A steel strip can be produced which in spite of its high manganese content has good deformation behaviour in that, according to the invention, from a steel which comprises more than 12 to 30 weight % of manganese, a roughed strip (V) is cast close to the final dimensions in a double-roller casting machine ( 2 ), said roughed strip comprising a thickness of up to 6 mm. Following casting, this roughed strip is further processed to form a continuous hot strip by preferably being rolled in a single hot roll pass.
Compound 529271: 1-Hexyne, 3,5-dimethyl

Chemical compound data from PubChem database. IUPAC Name: 3,5-dimethylhex-1-yne. Molecular Formula: C8H14. Molecular Weight: 110.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Child Welfare Information Gateway Survey

Via Reginfo: The Adoption Call to Action is an effort by the Children's Bureau, Administration for Children and Families of the U.S. Department of Health and Human Services. The purpose of the Adoption Call to Action is to engage child welfare agencies to improve the timeliness and likelihood of permanency for children who are waiting for adoption. Fifty-three jurisdictions are participating with each receiving technical assistance support from the Capacity Building Center for States, a Children’s Bureau funded provider. Each jurisdiction is involved in developing and implementing innovative solutions to achieve the goals established for this initiative. Lessons learned from this data collection will not only provide an assessment of the overall effectiveness of this initiative but will inform similar efforts in the future. This new information collection will provide the Children’s Bureau with an understanding of agency target populations, specific strategies (interventions), and outcomes measurement, in order to inform technical assistance strategies and provide a national picture of the overall success of the initiative. Baseline data will be collected with an initial survey (Baseline Survey), with two follow-up survey instruments (Progress Update Survey) designed to collect process and outcome measures at two additional points in time. The instruments focus on (1) identifying the target population(s) agencies are addressing, (2) understanding elements of intervention implementation (process measures), and (3) capturing information related to the outcomes of these efforts. Respondents of these data collection instruments will include one representative from each of the 53 child welfare agencies who are participating in Adoption Call to Action activities. Respondents will be able to use their own responses to this data collection to support their jurisdiction’s efforts to document and monitor progress and to communicate with stakeholders. Aggregate reporting will be developed from this data collection at each of the three points of data collection to provide TA providers and the Children’s Bureau with progress updates that can be used to developed more effective and tailored approaches to assistance.

<b>Units of Response: </b>Child Welfare Agencies

<b>Type of Data: </b>Survey

<b>Tribal Data: </b>Unavailable

<b>COVID-19 Data: </b>Unavailable

<b>Periodicity: </b>Irregular

<b>SORN: </b>Not Applicable

<b>Data Use Agreement: </b>Unavailable

<b>Data Use Agreement Location: </b>Unavailable

<b>Equity Indicators: </b>Unavailable

<b>Granularity: </b>Unavailable

<b>Spatial: </b>United States

<b>Geocoding: </b>Unavailable
Compound 530754: o-Methoxybenzoic acid, 2-isopropoxyphenyl ester

Chemical compound data from PubChem database. IUPAC Name: (2-propan-2-yloxyphenyl) 2-methoxybenzoate. Molecular Formula: C17H18O4. Molecular Weight: 286.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
AFCARS Report #15

This report provides preliminary estimaes of AFCARS data for FY 2007. Preliminary reports of AFCARS data include data received by September 30 for the report period ending March 31 and by March 31 for the report period ending September 30. This generally encompasses the required data submissions and submission of corrected data by States to avoid possible financial penalties.

Metadata-only record linking to the original dataset. Open original dataset below.
NNDSS - Table II. Cryptosporidiosis to Dengue virus infection

NNDSS - Table II. Cryptosporidiosis to Dengue virus infection - 2018. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states or territory.

Note:

This table contains provisional cases of selected national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up.  Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html 

Footnotes:

C.N.M.I.: Commonwealth of Northern Mariana Islands. 	
U: Unavailable. —: No reported cases. N: Not reportable. NA:  Not Available.  NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. 

* Case counts for reporting years 2017 and 2018 are provisional and subject to change. Data for years 2013 through 2016 are finalized. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf.  

† Includes data for dengue and dengue-like illness.
Detroit: Drug-Related Emergency Department Visits, 2004-2011 - All Visits

Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits in the Detroit metropolitan area, covering 2004-2011. File includes all drug-related ED visits that are reportable to DAWN without regard for the reason for the visit or the specific drugs involved. It includes visits involving all forms of drug misuse or abuse plus visits resulting from adverse reaction, accidental ingestion, suicide attempts, and visits where patients were seeking detoxification services. These estimates are useful for looking at overall levels of drug involvement in ED visits.File includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol.  Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology.Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
Compound 525370: tert-Butyl Isopropyl sulfide

Chemical compound data from PubChem database. IUPAC Name: 2-methyl-2-propan-2-ylsulfanylpropane. Molecular Formula: C7H16S. Molecular Weight: 132.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Research Article: Arthritis Research

Synovial fibroblasts (SFs) have become a major target for ex vivo gene transfer in rheumatoid arthritis (RA), but efficient transduction of RA-SFs still is a major problem. The low proliferation rate and heterogeneity of RA-SFs, together with their lack of highly specific surface receptors, have hampered a more extensive application of this technique. Improving transduction protocols with conventional viral vectors, therefore, as well as developing novel strategies, such as alternative target cells, and novel delivery systems constitute a major challenge. Recent progress in this field will lead to the achievement of high transgene expression, and will facilitate the use of gene transfer in human trials.
Compound 530642: m-Toluic acid, 2,6-dimethylnon-1-en-3-yn-5-yl ester

Chemical compound data from PubChem database. IUPAC Name: 2,6-dimethylnon-1-en-3-yn-5-yl 3-methylbenzoate. Molecular Formula: C19H24O2. Molecular Weight: 284.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Wolbachia: Evolutionary novelty in a rickettsial bacteria

Background
          Although closely related, the alpha-proteobacteria Wolbachia and the Rickettsiacae (Rickettsia and Ehrlichia), employ different evolutionary life history strategies. Wolbachia are obligate endocellular symbionts that infect an extraordinary host range and, in contrast to the infectious and pathogenic Rickettsia and Ehrlichia, profoundly influence host reproductive biology.
        
        
          Results
          Phylogenies of the Rickettsia, Ehrlichia, and Wolbachia were independently inferred from 16S rDNA sequences and GroEL amino acid sequences. Topologies inferred from both sets of sequence data were consistent with one another, and both indicate the genus Wolbachia shared a common ancestor most recently with Ehrlichia. These two genera are a sister group to the genus Rickettsia. Mapping biological properties onto this phylogeny reveals that manipulation of host reproduction, characteristic of Wolbachia strains, is a derived characteristic. This evolutionary novelty is accompanied by the loss of the ability to infect vertebrate hosts.
        
        
          Conclusions
          Because of the contrasting transmission strategies employed by each, Wolbachia is expected to maximize efficiency of vertical transmission, while Ehrlichia and Rickettsia will optimize horizontal transfer of infection. Wolbachia manipulation of host reproduction could thus be viewed as strategy employed by this bacterium to foster its own propagation via vertical transmission.
NNDSS - TABLE 1Y. Mumps to Novel influenza A virus infections

NNDSS - TABLE 1Y. Mumps to Novel influenza A virus infections - 2019. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. 

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
† Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). 
§ Novel influenza A virus infections are human infections with influenza A viruses that are different from currently circulating human seasonal influenza viruses. With the exception of one avian lineage influenza A (H7N2) virus, all novel influenza A virus infections reported to CDC since 2012 have been variant influenza viruses.
Patent AT-E399842-T1: [Translated] LIQUID DETERGENT

Chemical patent from PubChem database. Patent Number: AT-E399842-T1. Title: Polymorphic Forms of Active Compounds. Filing Date: 1995-11-24. Inventors: Kim, Young-Soo, Taylor, Elizabeth. Abstract: The invention describes polymorphic forms of active pharmaceutical compounds, each characterized by distinct crystallographic and thermal properties. IPC Classifications: B01J, C07C, C07D. This patent covers 20 claims related to 4 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Compound 530114: 5-Aminouracil, TMS

Chemical compound data from PubChem database. IUPAC Name: N-trimethylsilyl-2,4-bis(trimethylsilyloxy)pyrimidin-5-amine. Molecular Formula: C13H29N3O2Si3. Molecular Weight: 343.64. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526510: 2-Isothiocyanato-3-phenyl-propionic acid ethyl ester

Chemical compound data from PubChem database. IUPAC Name: ethyl 2-isothiocyanato-3-phenylpropanoate. Molecular Formula: C12H13NO2S. Molecular Weight: 235.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528956: Phenol, 2-(1-methylheptyl)-6-nitro

Chemical compound data from PubChem database. IUPAC Name: 2-nitro-6-octan-2-ylphenol. Molecular Formula: C14H21NO3. Molecular Weight: 251.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.